Skip to contentA
Anika Therapeutics, Inc.
A
ANIKAnika Therapeutics, Inc. Q1 2022 · 10-Q
Revenue$36.69M$36.69M+7.0% vs Q1 2021 Net Income-$2.93M-$2.93MN/M vs Q1 2021 EPS Diluted-$0.20-$0.20N/M vs Q1 2021 Gross Profit$21,804,000+4.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
Operating Cash Flow-$1,869,000N/M Free Cash Flowderived-$3,195,000N/M Margins · derivedGross margin59.4%−1.7 pt vs Q1 2021
Operating margin-9.7%−13.4 pt vs Q1 2021
Net margin-8.0%−16.3 pt vs Q1 2021
ended Mar 31, 2022 · filed May 6, 2022 · 36 d after period end